• Explore /
  • Poster
  • / Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosome–positive (Ph+) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).

Outcomes with inotuzumab ozogamicin (InO) in patients with Philadelphia chromosome–positive (Ph+) relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).

Abstract Poster

Authors

null

Wendy Stock

Section of Hematology/Oncology, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, IL

Wendy Stock , Giovanni Martinelli , Matthias Stelljes , Daniel J. DeAngelo , Nicola Gökbuget , Anjali S. Advani , Susan Mary O'Brien , Michaela Liedtke , Akil Abid Merchant , Ryan Daniel Cassaday , Tao Wang , Erik Vandendries , David I. Marks , Hagop M. Kantarjian

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT01363297

Citation

J Clin Oncol 36, 2018 (suppl; abstr 7030)

DOI

10.1200/JCO.2018.36.15_suppl.7030

Abstract #

7030

Poster Bd #

90

Abstract Disclosures

Similar Posters

Poster

2020 ASCO Virtual Scientific Program

Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP).

Inotuzumab ozogamicin (INO) plus bosutinib (BOS) in R/R PH+ ALL or CML in lymphoid blast phase (CML LBP).

First Author: Nitin Jain

First Author: Jeremy Chang

First Author: Nicholas James Short

First Author: Cristina Papayannidis